SynthesisPloS one2020
Prevalence of antiphospholipid antibodies in Behçet's disease: A systematic review and meta-analysis.
Synthesis in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Global epidemiology of hepatitis B virus infection in dialysis patients: a systematic review and meta-analysis of prevalence, immunity, risk factors, and beyond.International urology and nephrology · 2026Pooled it
- Global epidemiology of HIV among dialysis patients: a systematic review and meta-analysis.International urology and nephrology · 2025Pooled it
- Meta-analysis of anti-BMJ open · 2020Pooled it
- The Role of Viral and Bacterial Infections in the Etiology of Behçet's Disease.Journal of clinical laboratory analysis · 2026Review
- [Clinical significance of antiphospholipid antibodies in Behcet disease with thrombosis].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2024Article
- C-reactive Protein (CRP) in Patients With Myocarditis: A Systematic Review and Meta-Analysis.Cureus · 2024Review
- Internal Jugular Vein Thrombosis as the Initial Presentation of Antiphospholipid Antibody-positive Vascular Behçet Disease: A Clinical Image.Journal of community hospital internal medicine perspectives · 2024Article
- Positive antiphospholipid antibodies: observation or treatment?Journal of thrombosis and thrombolysis · 2023Review
- Article
- Integrative metabolomics of plasma and PBMCs identifies distinctive metabolic signatures in Behçet's disease.Arthritis research & therapy · 2023Article
- Rare paediatric cardiopulmonary presentation of Behcet's disease.BMJ case reports · 2022Article
- Review
- Frenemies within: An Endocarditis Case in Behçet's Disease.Journal of personalized medicine · 2021Article
- Behçet's Syndrome Apart From the Triple Symptom Complex: Vascular, Neurologic, Gastrointestinal, and Musculoskeletal Manifestations. A Mini Review.Frontiers in medicine · 2021Review
- Indication and outcome of lupus anticoagulant and antiphospholipid antibodies testing in routine clinical practice.Rheumatology advances in practice · 2021Article
- Imperfect storm: is interleukin-33 the Achilles heel of COVID-19?The Lancet. Rheumatology · 2020Review
- MicroRNA (miRNA): A New Dimension in the Pathogenesis of Antiphospholipid Syndrome (APS).International journal of molecular sciences · 2020Review
- The Pathophysiology of The Antiphospholipid Syndrome: A Perspective From The Blood Coagulation System.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Behçet's disease (BD) is a multifactorial systemic inflammatory disease of unknown aetiology characterised by several clinical manifestations including vascular involvements (i.e., both arterial and venous thrombosis). Antiphospholipid antibodies (aPLs)-including anticardiolipin (aCL), anti-β2-glycoprotein I (β2-GPI) antibodies and lupus anticoagulant (LA) are detected in systemic autoimmune diseases which contribute to thrombosis. The aim of this systematic review and meta-analysis was to evaluate the prevalence of aPLs in patients with BD as compared to controls. A protocol was registered in PROSPERO (Registration No. CRD42018088125) and a systematic literature search was conducted through PubMed, Web of Science, Embase, Scopus and ScienceDirect databases. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using random-effects model. Quality assessment was carried out by using the modified 9-star Newcastle-Ottawa Scale (NOS). Publication bias was evaluated via visualisation of contour- enhanced and trim and fill funnel plots along with Begg's and Egger's tests. We included ten case-control studies (a total of 999 participants from 380 BD patients and 619 controls) based on the inclusion criteria. The prevalence of aCL (OR: 12.10, 95% CI: 5.15-28.41, p<0.00001) and anti-β2-GPI antibodies (OR: 23.57, 95% CI: 1.31-423.63, p = 0.03) were statistically significant, however, the prevalence of LA was not significant (OR: 13.77, 95% CI: 0.65-293.59, p = 0.09). The results remained statistically significant from different sensitivity analyses which represented the robustness of this meta-analysis. According to the NOS, 50.0% of the studies were considered as of high methodological quality (low risk of bias). No significant publication bias was detected from contour-enhanced and trim and fill funnel plots or Begg's and Egger's tests. This meta-analysis established that there is a significantly high prevalence of aPLs (i.e., aCL and anti-β2-GPI antibodies) in patients with BD when compared to controls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.